Where Can You Actually Get Microdose Tirzepatide? 5 Real Options in 2026

The 5 tirzepatide microdose options, one by one

Start with the line that sounds like you:

• Lowest price: Mochi Health, about $170 a month at its lowest dose.
• Small weight goal or keeping weight off: BetterMe Rx, if you can pay a year upfront.
• A firm cap on the dose: Lemonaid Health, which keeps doses at a quarter of a standard maintenance dose.
• Wellness, not weight loss: Fridays, though its benefits are unproven.
• You only want an FDA-approved drug: Zepbound at its 2.5 mg starting dose, from Lilly.

Mochi Health: the cheapest low-dose tirzepatide

Mochi Health has a microdosing plan for semaglutide or tirzepatide. Its tirzepatide is compounded, meaning a pharmacy mixes it rather than Lilly making it. Since August 2026, Mochi prices medicine by dose. So the microdose is simply the cheapest step of its normal price ladder. That ladder starts at 2.2 mg, just under Zepbound's first dose.

Tirzepatide medicine starts at about $90 a month at the lowest dose. It tops out near $200 at the highest. The membership adds about $80 a month. Paying a year of membership upfront brings that to about $50 a month.

New members get the first month of membership free on the monthly plan, though not in every state. Mochi now works as a pharmacy marketplace. So these are floor prices that can vary by pharmacy.

It suits a first-time user who wants the lowest bill without prepaying. Our Mochi Health review covers its pharmacies and reputation.

BetterMe Rx: a microdose plan for small goals

BetterMe Rx sells a separate microdosing program with compounded tirzepatide shots. It is aimed at losing 5 to 20 pounds or keeping weight off.

The price stays the same as the dose changes. Visits and shipping are included. It costs about $235 a month. On a 12-month plan paid upfront, it drops to about $185 a month. That is one charge of about $2,220.

Keep two cautions in mind. Its page quotes weight loss of up to 22%. That figure comes from full-dose trials, not from microdoses. Also, nothing is refunded once an order is processed.

BetterMe Rx also sells tirzepatide tablets. No published trial shows that swallowed tirzepatide works.

Fridays: a microdose sold for wellness

Fridays sells Compounded Microdose Tirzepatide, a weekly shot, for about $200 a month. It sits in a separate Microdosing section, apart from its weight-loss program.

Fridays says the shot suits people already stable on a GLP-1 medicine, without a weight-loss focus. It pitches steady energy, mental clarity and fewer side effects. Its own page also says compounded microdose formulas have not been studied for those outcomes. Our Fridays review covers the rest of its program.

Lemonaid Health: a microdose with a firm cap

Lemonaid Health sells compounded tirzepatide microdoses for about $200 a month. A required membership adds about $50 a month. That comes to about $250 a month in all.

Lemonaid caps the dose at 25% of a standard maintenance dose. Its pitch is a slower pace with fewer side effects. The same cap applies to its semaglutide microdoses, covered in our semaglutide microdosing comparison.

It costs more than Mochi Health each month. It suits you if a clear upper limit on the dose matters most.

Lilly self-pay: Zepbound at its starting dose

Zepbound is the FDA-approved tirzepatide for weight loss. Its first dose is 2.5 mg a week. Without insurance, it costs about $300 a month from Lilly. You need a prescription.

You can buy it from LillyDirect, Lilly's online pharmacy, as a vial or a KwikPen. The KwikPen is also sold at that price in local pharmacies. Lilly's current self-pay terms run through December 31, 2026.

It is not sold as a microdose. The label says 2.5 mg is for starting treatment and is not approved as a maintenance dose. But it is the only option here with no question about compounding.

Not on the list: Noom

Noom's Microdose GLP-1Rx is the name many women expect here. It uses compounded semaglutide, not tirzepatide. Noom offers tirzepatide only as brand-name Zepbound or Mounjaro.

What counts as a microdose of tirzepatide?

The FDA has no definition of a tirzepatide microdose. So the word means different things depending on who sells it.

Zepbound and Mounjaro both start everyone at 2.5 mg a week. The label calls this a starting dose, used to ease the body in. In that sense, the FDA's own first step is the closest thing to an official microdose.

Sellers usually mean something smaller than that first step, raised slowly. Lemonaid, for example, caps doses at a quarter of a standard maintenance dose. That is marketing language, not a clinical guideline. No standard protocol exists.

What does tirzepatide microdosing cost over a year?

At the same low dose all year, the totals look like this:

• Mochi Health: about $1,670 with a prepaid year of membership. About $2,030 if you pay month to month.
• BetterMe Rx: about $2,220 on the 12-month plan paid upfront.
• Fridays: about $2,375 at its monthly price.
• Lemonaid Health: about $2,975 at its monthly price.
• Zepbound 2.5 mg from Lilly: about $3,890 for 13 four-week fills. The label treats that dose as a starting step only. Lilly's KwikPen offer covers up to 11 fills a year, and its terms end December 31, 2026.

None of these prices mentions lab tests. For tirzepatide at standard doses, our cheapest tirzepatide providers page compares many more options.

Where a microdose sits on the tirzepatide dose ladder

The Zepbound and Mounjaro labels climb in 2.5 mg steps, at least four weeks apart, up to 15 mg. A compounded microdose usually stays below the first step.

Your prescriber decides each step. For missed doses and the full ladder, see the tirzepatide dosage chart.

Can a lower or less frequent dose keep the weight off?

This is the use Fridays pitches. The idea is to hold your results once you reach your goal, not to start fresh.

A small 2025 paper in the journal Obesity looked at a related idea. It studied the same dose, taken less often. It described two real patients plus a computer model of semaglutide and tirzepatide. Most of the weight loss held with 2 or 3 weeks between doses, perhaps even 4. The authors said this supports a hypothesis that needs more research.

That is not proof. It also tested spacing, not smaller doses. Any change to your dose or schedule is a decision to make with your prescriber.

Is there real science behind tirzepatide microdosing?

Not yet. No trial has tested a long-term tirzepatide microdose, for weight loss, inflammation or anything else.

Lilly's first human study did give doses as small as 0.25 mg. But that was a single dose, or four weeks at most, in healthy people. It measured safety and how the body handles the drug, not results.

Tirzepatide acts on two gut-hormone targets, called GIP and GLP-1 receptors. Semaglutide acts on GLP-1 only. That dual action is real, but it has not produced its own microdosing evidence.

SURMOUNT-1, the trial behind Zepbound, tested 5, 10 and 15 mg. Higher doses brought more weight loss. It did not test doses below the starting dose. Claims about inflammation or longevity remain unproven in people.

Are the side effects gentler at a microdose?

Maybe, but nobody has measured it. In the Zepbound trials, most nausea, vomiting and diarrhea happened while the dose was being raised. These effects then eased over time. That suggests a lower dose could be gentler. No trial has measured side effects on a long-term dose below 2.5 mg. Our tirzepatide side effects guide has the numbers at approved doses.

The Zepbound label links hair loss to weight reduction. In its trials, about 7% of women on Zepbound reported hair loss, against about 1% on placebo. Slower loss may mean less shedding, though no study has checked this for microdoses.

Some risks do not shrink with the dose. The label's boxed warning, its strongest kind, covers thyroid C-cell tumors seen in rodent studies. It applies at any dose. Pancreatitis and gallbladder problems are listed warnings too.

Is a tirzepatide microdose a good start in perimenopause?

Perimenopause can already bring nausea and bloating. So a gentler, slower start has real appeal. It may mean fewer rough early weeks.

Slower weight loss may also be easier on muscle. That matters when falling estrogen already works against lean mass. Our guide to GLP-1s and muscle loss in perimenopause covers that trade-off.

If you still take the pill for birth control, the label has one more point. It advises switching to a non-oral method, or adding a barrier method like condoms. That applies for 4 weeks after starting and for 4 weeks after each dose increase.

The other side is simple. A low dose trades some certainty of results for comfort. In tirzepatide's trials, the higher maintenance doses did more. If real weight or blood sugar change is the goal, a standard climb to a maintenance dose has stronger evidence.

How to tell a legitimate low-dose plan from a DIY red flag

What matters most is who manages the dose. A legitimate plan comes from a licensed prescriber and a named compounding pharmacy. Your provider sets the dose and can change it.

These are red flags:

• You draw your own reduced dose from a vial.
• You buy an unlabeled microdosing kit online.
• You split a pen or vial yourself.

Lilly says its single-dose Zepbound vials contain no preservative. It does not recommend splitting them into smaller doses.

Compounded tirzepatide also has a narrower legal path than it once did. The FDA declared the tirzepatide shortage over in December 2024. Smaller 503A pharmacies, which make medicine for one patient at a time, had until February 2025 to stop shortage-era copies. Larger 503B outsourcing facilities had until March 2025.

A 503A pharmacy can still make tirzepatide for one patient with a prescription. It cannot simply copy the approved drug. On April 30, 2026, the FDA proposed not adding tirzepatide, semaglutide and liraglutide to the list that 503B facilities can compound from. Comments closed on July 30, 2026. No final decision has been published.

If a seller cannot name its pharmacy or its prescriber, walk away.